

Doc Ophthalmol
DOI 10.1007/s10633-010-9226-1

REVIEW ARTICLE

The electroretinogram: a useful tool for evaluating age-related macular disease?

Emma J. Berrow · Hannah E. Bartlett ·
Frank Eperjesi · Jonathan M. Gibson

Received: 22 September 2009 / Accepted: 2 March 2010
Springer-Verlag 2010

Abstract With an ageing population, the number of age-related macular disease (ARMD) cases will inevitably rise. This gives greater impetus for the need to identify the disease earlier and assess treatments to slow disease progression. Differing electroretinogram (ERG) modalities have been reviewed in relation to the objective assessment of retinal function in ARMD and for monitoring the effectiveness of clinical interventions. Conflicting results have been found with regard to the efficacy of ERG findings in the investigation of ARMD in previous years. The newer multifocal ERG paradigm provides spatial topographical information about retinal function in ARMD. It has shown promising results in monitoring effectiveness of clinical interventions and studies are continuing in this area. Better knowledge of retinal function in ARMD may lead to enhanced treatments at each phase of the disease.

Keywords Electroretinography Maculopathy
Age-related macular degeneration
Multifocal electroretinogram

Introduction

In the majority of clinical studies of ARMD, visual acuity is used as a measure of macular function. However, this is far from ideal as it assesses one small area of the retina, does not provide an overall measure of macular function and relies on subjective patient responses. It is important to identify individuals who are at most risk of developing the ARMD, so that interventions and lifestyle modifications can be targeted appropriately. In asymptomatic eyes, sensitive, reproducible measures of macular function are important to highlight the earliest signs of ARM. The objectivity and the topographical mapping that multifocal electroretinography (mfERG) provides allows for assessment of localised retinal cell function deficits in ARM over time. Evidence also suggests that mfERG can be used to monitor effectiveness of surgical and clinical intervention. This review enumerates the efficacy of various types of electroretinogram (ERG) for assessing retinal function in ARMD.

Age-related macular degeneration (AMD) is the leading cause of visual loss in the developed world [1]. Age-related maculopathy (ARM) is characterised

E. J. Berrow (✉) · H. E. Bartlett · F. Eperjesi
J. M. Gibson
Ophthalmic Research Group, School of Life and Health
Sciences, Aston University, Birmingham B4 7ET,
United Kingdom
e-mail: berrowej@aston.ac.uk

E. J. Berrow · J. M. Gibson
Heart of England NHS Trust, Birmingham,
United Kingdom

Published online: 16 March 2010

123

by drusen (C63 Zm) with or without retinal pigment epithelium (RPE) changes and often precedes AMD. The term 'age-related macular disease (ARMD)' encompasses both ARM and AMD [2].

The RPE phagocytises the outer segment discs of the photoreceptors and is a point of metabolite and waste exchange, which is considered crucial to retinal function [3]. The earliest signs of ARMD are seen as variation in the pigmentation of the RPE, with or without the presence of drusen [4]. Oxidative stress may cause injury and inflammation to the RPE and choriocapillaris leading to an altered extracellular matrix, affecting nutrient supply to the RPE and retina, possibly further damaging the RPE and retina, leading to the retinal atrophy seen in AMD [5]. Ophthalmic electrophysiology can be used to measure the function of the choroid, RPE and the photoreceptor layer [6] and has therefore been shown to be a good means of objectively quantifying retinal function. RPE changes seen in AMD can be measured by the electrooculogram (EOG). Electroretinography assesses photoreceptor and post-receptoral retinal function. The differing ERG techniques are easily and non-invasively obtained with an active corneal electrode, reference electrode and ground electrode where electrical activity within the retina is studied using presentation of visual stimuli. Different stimuli used for differing ERG techniques allow for functional quantification of various retinal cells, each of which is discussed in the following sections.

Full-field electroretinogram (ERG)

The full-field or flash ERG (ffERG) generally consists of a negative deflection, called the a-wave, which is mainly associated with the photoreceptors and a positive b-wave, thought to be produced by ON bipolar cell depolarisation. Scotopic ffERGs elicit rod-dominated photoreceptor function responses and photopic conditions elicit cone-function responses. A 30-Hz light stimulus ERG also provides information about cone function, whilst oscillatory potentials reflect amacrine cell function [7]. ARMD can subtly affect areas of the retina unseen on clinical fundoscopy due to generalised retinal ischaemia [8] and altered retinal nutrient and waste exchange [5], thus ffERG changes may be apparent when ophthalmoscopy findings show very little.

The ffERG gives a massed retinal electrical response to a light stimulus but does not provide spatial retinal information. Thus, small retinal lesions such as those seen in ARM may be missed by ffERG, and so there have been contradictory findings reported for the appropriateness of using ffERG in the assessment of the condition [9–12]. Holopigian et al. examined the effect of normal ageing, ARM and AMD on the ffERG. They demonstrated reduction of amplitudes and increase in implicit times of the ffERG over time with increasing age for normal subjects, as well as those with ARM and AMD under photopic and scotopic conditions [12]. Similarities between older normal subjects and those with ARM highlight the importance of using age-matched normals for comparison when observing older subjects with ARMD. These results correlated with the findings of other studies showing a decrease in rod and cone ERG amplitudes with age [13] and a slowed inactivation of phototransduction in rod photoreceptors with age when measuring the recovery of the a-wave using a paired flash ERG technique [9]. Marcus et al. [11] studied the b-wave of the ERG in 24 eyes of 12 subjects with ARMD and found low to normal b-wave amplitudes in diseased eyes and no correlation with clinical morphology. However, there was no control group comparison.

Along with reduced and delayed photopic cone-dominated a-wave responses, scotopic rod-dominated a- and b-wave responses have been examined in ARMD using the ffERG. These were also reduced and delayed, suggesting that ARMD affects rod as well as cone photoreceptors [10]. A review by Scullica and Falsini [14] identified that studies of retinal function in ARM and AMD have found substantial impairment of rod photoreceptor function. Inconsistency exists in the literature about the value of ffERG in ARMD. As the ffERG is a massed response, the sensitivity of the test is limited when trying to assess small lesions as observed in ARM [15].

Pattern ERG

The pattern ERG (PERG) occurs with pattern reversal stimulation, typically a checkerboard pattern of mean overall luminance, which isolates non-linear retinal responses while cancelling linear responses [16]. This

gives a direct measure of ganglion cell function and allows discrimination between optic nerve and macular disease [17]. Pattern ERG abnormalities have been seen in AMD and reduced PERG P50 amplitudes have been observed in maculopathies [17]. The PERG has been shown to be abnormal in macular dysfunction when there is no detectable change in the fFERG [18]. Since the PERG measures ganglion cell function [17] and ganglion cell function remains relatively preserved in AMD [19], it may be argued that PERG does not provide sufficient information about retinal function in ARMD, especially in ARM when only small areas of drusen are seen. The PERG elicits an inner retinal response whereas ARMD is a retinal degeneration primarily affecting the RPE and the choriocapillaris [12].

The PERG has been effective at assessing retinal function in AMD when clinical interventions are undertaken. Neveu et al. [20] demonstrated that a detectable PERG prior to photodynamic therapy (PDT) in eyes with choroidal neovascularisation (CNV) was the single best indicator for improvement in visual acuity following treatment. However, in ARM, the area of retinal lesion is usually smaller than the area of PERG recording making the PERG less effective at monitoring ARM compared to angiography. The PERG fails to provide any spatial retinal information. Another study examining PERG at the early stages of PDT for CNV showed a reduction in amplitudes and delay in latencies of the P50 and N95 soon after PDT which resolved at 1 month [21]. Mackay et al. [19] assessed longer term changes to the PERG over 12 months and found that the P50 and N95 amplitude reduced over the 12 months, without recovery. The P50 latency reduced over the year but then increased at 12 months. However, this finding was not statistically significant.

Focal ERG

Unlike the fFERG, the focal ERG (fERG) has the ability to specifically stimulate the fovea—useful when evaluating macular disease [22, 23]. A flickering light stimulus is utilised to stimulate the macular region and measures macular cone photoreceptor and bipolar cell function [24]. Although there is no international procedural standard set for undertaking

this ERG technique, a number of varying techniques for recording fERG have been described in the literature. Differing field sizes (3–18°) and light stimulus frequencies have been used. Seiple et al. [25] examined retinal function in ARMD using a range of stimulus frequencies (10–60 Hz). This work showed fERG amplitude losses at high and low frequencies in patients with macular disease, but relative sparing of the mid-temporal frequencies although the type and severity of ARMD was not noted within the results or separated out from other macular diseases.

Research on fellow eyes of patients with unilateral CNV has suggested that these eyes have a normal foveal cone number but abnormal cone function, indicated by delayed implicit times. Results were adjusted for age, gender, iris pigmentation and spherical equivalent [26]. Another study confirmed these findings and is postulated to be due outer retinal ischaemia [27]. Normal fERG phase but decreasing amplitudes have been documented with increasing severity of non-exudative AMD [28].

Nutritional supplementation and its effects on macular function have been investigated in subjects with ARM and age-matched normals. Falsini and colleagues [29] found that at 180 days, normal and ARM eyes showed an increase in fERG amplitudes after vitamin E and nicotinamide supplementation. At 360 days, amplitudes were maintained.

Binns and Margrain [30] proposed a fERG photostress modality to examine retinal function in ARM, using intense light adaptation to bleach the retina, followed by periodical fERG to examine the recoverability of retinal function and determine the rate of photopigment regeneration. Retinal function recovery rate was slower in those with ARM compared to controls suggesting impairment in the ability of the outer retina to regenerate cone photopigment.

The effect of age on the fERG has been detailed, showing decreasing amplitude with increasing age [23, 26] and increasing fERG implicit times [26], stressing the need for age-matched controls when investigating ARM and AMD with fERG.

Focal ERG is useful for assessing retinal function in ARM and AMD. However, good fixation is required and it is limited to a single area, thus giving no information about multiple areas of retinal function. Also, no international procedural standard has yet been determined.

Multifocal ERG

The multifocal ERG (mfERG), developed by Sutter and Tran [31], is based on a pseudorandom M-sequence stimulation technique that allows simultaneous recording of ERGs from many retinal areas at once [32]. Like PERG, fERG and ffERG, it is an objective measurement of retinal function but in contrast to these tests the mfERG allows simultaneous measurements of multiple responses at different retinal locations [33, 34]. The first-order kernel of the mfERG waveform comprises of a negative N1 component, a positive P1 component and a negative N2 component. Hood's very comprehensive literature on mfERG suggests that mfERG responses are similar to the ffERG in that the N1 of the first-order kernel of the mfERG is cone-driven (as in a photopic ffERG) and that the P1 contains responses from the bipolar cells [35]. The mfERG is dominated by bipolar cell activity and so a disease that substantially decreases the mfERG amplitude must therefore be acting at or before the bipolar response [7]. The first-order kernel is the most commonly measured parameter of the mfERG. The mfERG also contains a second order kernel which originates from induced components of the inner retina, more details of which can be understood in the work of Sutter [36–38]. The mfERG maps retinal function within the central 30–50° of the retina and good fixation is required for accurate results, suggesting it may be better suited to assessment of retinal function in ARM where central vision is preserved.

Various studies have reported the efficacy of the mfERG in the assessment of ARMD [6, 19, 20, 29, 33, 39–58].

Eyes with ARM have been found to have reduced foveal mfERG P1 amplitudes and increased N1 latencies when compared with age-matched normal controls [46]. Interestingly, asymptomatic fellow eyes of the ARM eyes in this study also exhibited the same findings, suggesting that the mfERG may be a sensitive means of detecting early ARM changes. Feigl et al. [59], in contrast, found no such correlation, possibly attributable to non-uniform use of grading and classification systems and varying age range of the participants used in the different studies.

Research comparing the mfERG between exudative AMD, non-exudative ARM and normal controls has been undertaken [44] demonstrating reduction in

the P1 and N1 amplitudes of both CNV and ARM eyes when compared with controls. However, although the average age of the CNV and ARM groups were similar in this study (64.4 and 66.5 years, respectively), the control group was younger (57.7 years). This may account for some amplitude reduction due to ageing influence on the mfERG [60, 61]. Seiple et al. [62] demonstrated a significant linear relationship of 10.5% reduction in the N1 to P1 amplitude per decade, emphasising the importance of using age-matched controls when interpreting mfERG results.

The mfERG guidelines described by the International Society for Clinical Electrophysiology of Vision (ISCEV) [63], measures cone function. However, rod-mediated mfERG can be recorded after dark adaptation. It is time consuming with poorer signal-to-noise ratios than cone-mfERGs [64]. A study to compare rod- and cone-mediated mfERG in ARM showed reduced N1 and P1 amplitudes in ARM when compared to controls in both rod- and cone-mediated mfERGs [47]. Delayed rod-mediated mfERG P1 implicit times in ARM eyes were reported when compared with age-matched normal controls [50, 52, 53], implying that both rod and cone function is affected in ARM. However, further work using larger sample sizes would provide more definitive rod-mfERG information, as to date conflicting results have been demonstrated.

Interesting work has been undertaken on the use of mfERG to investigate the role of ischaemia in ARM. Hypoxia has been experimentally induced in younger and older healthy eyes resulting in a reduction in central and peripheral neuroretinal function indicated by reduced mfERG response densities [41, 65, 66]. This supports the hypothesis that post-receptor vulnerability occurs during reduced oxygenation and ischaemia [52, 67].

Differing mfERG paradigms have been used to evaluate rod and cone systems in ARM. Global-flash mfERGs have been used in an attempt to overcome some of the conflicting findings that have been observed with the conventional mfERG and to better reflect adaptation deficits in ARM [51]. The findings indicate that the global-flash mfERG detects reduced adaptation responses before the conventional mfERG. Thus, it could be argued that global-flash mfERG may be more beneficial in identifying ARM sooner than the standard mfERG. More research is necessary to consolidate this hypothesis.

The slow flash mfERG is another paradigm that has been subtracted from the conventional fast flicker mfERG to assess non-linear adaptive components within the retina in ARM [48]. Interestingly, neither conventional mfERG nor slow flash mfERGs discriminated between the ARM group and age-similar controls. However, the difference between the two paradigms showed a reduced late component waveform in the ARM group compared to the control group suggesting post-receptor adaptation abnormalities in the ARM group.

Comparison between the conventional cone-mediated mfERG response and morphological changes in ARM have been examined [40, 49, 68], with outcomes suggesting slight increase in delayed implicit time with drusen progression, drusen regression with increasing RPE changes and in stable drusen. After more than 2 years, the responses became more delayed with reduced response density. The mfERG changes were not limited to the drusen areas in these studies, suggesting retinal function does not correlate directly with morphology in ARM.

The objectivity of the mfERG in assessing retinal function correlates well with subjective macular function tests in ARM and AMD [39], such as colour vision [49] and microperimetry testing [69] and suggests they may be significantly related to retinal function in the cone-mediated mfERG in ARM.

Multifocal ERG in clinical intervention studies

mfERG has been investigated as a tool for assessing retinal function before and after PDT, a widespread treatment for predominant classic CNV prior to the introduction of intravitreal ranibizumab and bevacizumab (Table 1).

Palmowski et al. [57] compared retinal function pre- and post-PDT in 16 eyes and found that after PDT the mfERG showed focal improvements in 13 eyes. In 10 eyes, focal retinal function deteriorated in some locations. At 15 weeks, some areas of the mfERG did not demonstrate any improvement when compared with mfERGs obtained at 3 weeks post-PDT. They concluded that improvement in parafoveal function can be seen with mfERG and deemed it a suitable tool in assessing retinal function in AMD.

Short-term mfERG changes were assessed in 17 eyes with CNV before and after PDT with verteporfin

by Jiang et al. [56] The mfERG latencies and response amplitude densities remained largely unchanged within 3 days, and at 1 week post-PDT with verteporfin when compared with pre-PDT mfERG. Their data suggests that verteporfin therapy may not result in adverse effects within the outer retina, in contrast to other histopathological studies assessing verteporfin and PDT in the monkey retina [70].

Multifocal ERG recordings were performed before PDT, and at 4 days, 2 weeks and 1 month after PDT with verteporfin in a study by Lai et al. [42]. Their research showed a transient impairment in retinal function that resolved after 1 month. In contrast to the work by Jiang et al., there was a change at 4 days post-PDT with reduced N1 and P1 response amplitude densities and increased P1 latencies. However, Lai's study contained only three AMD eyes with CNV, the other fourteen eyes being a mixture of myopic CNV, idiopathic CNV, polypoidal choroidal vasculopathy and central serous chorioretinopathy.

Studies at baseline and 6 weeks post-PDT were assessed with mfERG by Ruether et al. [71] showing a trend towards reduced P1 amplitudes and delayed latency, although these effects were not statistically significant and comparison to a non-treated group did not occur.

Catala-Mora et al. [72] observed mfERG changes over a longer period post-PDT in twenty-three eyes. At two and six months after treatment, the N1 and P1 amplitudes did not change and even improved in the more peripheral areas tested. They concluded that mfERG offers interesting non-subjective information about retinal sensitivity in macular diseases treated with PDT.

Mackay et al. [58] examined the use of mfERG as a predictor of vision maintenance post-PDT in neovascular AMD using logistic regression models. Patients with an average of 6/30 vision were less likely to respond to PDT than those with poor vision. Relatively good contrast sensitivity and large central mfERGs increased the probability of a response to PDT. In a further study, mfERG was assessed in pre- and post-PDT in CNV. They found P1 response amplitude density increased at 6 months and then returned to baseline at 12 months [19]. Work undertaken by Moschos et al. [73] demonstrated that although at 6 months post-PDT 70% of vision remained stable, there was a demonstrable reduction of mfERG response amplitude density, highlighting

Table 1 A summary of post-PDT mfERG studies

Reference	Sample size	Age in years Mean/range	ARMD status	Visual acuity pre-PDT	Mean mfERG findings pre-PDT	Follow-up duration after PDT	Visual acuity post-PDT	Mean mfERG findings post- PDT
Palmowski et al. Influence of photodynamic therapy in choroidal neovascularization on focal retinal function assessed with the multifocal electroretinogram and perimetry. <i>Ophthalmology</i> . 2002; 109(10):1788–92.	16 eyes of 16 patients	Not stated	Classic neovascular AMD	Median 0.2 range 0.05–0.8	Scalar product (SP) template used thus no pre-PDT mfERG information given	2–15 weeks	Median 0.3 range 0.04–1.25	SP improved in 16 locations SP reduced in 11 locations
Jiang et al. The changes of multifocal electroretinography in the early stage of photodynamic therapy for choroidal neovascularization. <i>Documenta Ophthalmologica</i> . 2003; 107(2):165–70.	17 eyes of 16 patients	55.2 (25–76)	12 exudative AMD eyes (11 cases) 2 myopic CNV 3 idiopathic CNV	Median 20/ 25 Range 20/ 25–20/125	Ring 1–6 N1 lat 21.39 Ring 1–6 P1 lat 40.29 Ring 1–6 N1 amp 7.84 Ring 1–6 P1 amp 17.44	3 days, 7 days	Median 20/25 range 20/ 25–20/125	Ring 1–6 N1 lat 21.58 Ring 1–6 P1 lat 40.39 Ring 1–6 N1 amp 7.91 Ring 1–6 P1 amp 17.63 (at 7 days)
Ruether et al. Testing central retinal function with multifocal electroretinography before and after photodynamic therapy. <i>Ophthalmologie</i> . 2003; 100(6):459–64.	25 eyes of 24 patients	71.3 range not given	12 classic subfoveal Neovascular AMD 9 Occult CNV AMD 4 myopic CNV	Mean 0.22 range not given	Centre amp 31.33 Ring 1 amp 20.67 Ring 2 amp 15.33	6 weeks	Mean 0.22 range not given	Centre amp 26.33 Ring 1 amp 18.33 Ring 2 amp 13.33
Moschos et al. Assessment of macular function by multifocal electroretinogram in age-related macular degeneration before and after photodynamic therapy. <i>J Fr Ophthalmol</i> . [Article]. 2004 Nov; 27(9):1001–6.	20 eyes of 20 patients	69.05 (range 30–80)	Classic subfoveal neovascular AMD	Mean 21.35 range 1–49 (ETDRS number of letters)	Mean retinal response amp density area 1 = 4.39, area 2 = 2.11	1 week, 3 months, 6 months	17.6 range 1–42 (ETDRS number of letters)	Mean retinal response amp density area 1 = 2.24 area 2 = 1.07

Table 1 continued

Reference	Sample size	Age in years Mean/range	ARMD status	Visual acuity pre-PDT	Mean mfERG findings pre-PDT	Follow-up duration after PDT	Visual acuity post-PDT	Mean mfERG findings post-PDT
Lai et al. Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. <i>American Journal of Ophthalmology</i> . 2004; 137(5):826–33.	17 eyes of 17 patients	50.5 (29–75)	3 AMD CNV 4 idiopathic CNV 4 myopic CNV 4 polypoidal choroidal vasculopathy 2 central serous chorioretinopathy	Median 20/ 70 range 20/30–20/ 100	Central N1 amp 9.97 Peripheral N1 amp 6.93 Central P1 amp 26.12 Peripheral P1 amp 19.40	4 days, 2 weeks and 1 month	Median 20/50 range 20/ 30–20/100 at 1 month	Central N1 amp 9.49 Peripheral N1 amp 6.52 Central P1 amp 25.05 Peripheral P1 amp 18.81 (at 1 month)
Feigl B et al. Dynamics of retinal function after multiple photodynamic therapies in age-related macular degeneration: A report of cases. <i>Doc Ophthalmol</i> . 2005 Apr 24–29; 111(3):135–48.	5 eyes of 5 patients	74 (64–81)	5 CNV AMD	Median 6/38 range 6/19–6/60	Pre-treatment figures not provided. Pre-treatment mfERG used as a waveform template with Matlab software to compare with post-treatment mfERG values	1,2 and 3 months	Median 6/48 range 6/38– 6/60	Cone-mfERG: Central a-scale = 1.0 paracentral a-scale = 1.3 pericentral a-scale = 1.3 central t-scale = 1.1 paracentral t-scale = 1.0 pericentral t-scale = 0.9 (all numbers are ratios at 3 months compared to pre-treatment values) Rod-mfERG: Overall a-scale = 0.9 Overall t-scale = 0.9 (all numbers are ratios at 2 months compared to pre-treatment values)
Catala-Mora et al. Multifocal electroretinogram and age-related macular degeneration. <i>Arch Soc Esp Oftalmol</i> . 2005; 80(7):395–404.	23 eyes of 22 patients	Not given	23 classic CNV AMD	20/21 (colenbr- ander)	See post-PDT column	2 months, 6 months	20/17 (colenbr- ander) at 6 months	Statistical significance was reached for ring 5 scalar product, ring 3 and ring 5 P1 amplitude, ring 3 P1 latency and in ring 5 N1 latency at 6 months compared to pre treatment values

Table 1 continued

Reference	Sample size	Age in years Mean/range	ARMD status	Visual acuity pre-PDT	Mean mfERG findings pre-PDT	Follow-up duration after PDT	Visual acuity post-PDT	Mean mfERG findings post-PDT
Mackay et al. Deficits in the electroretinogram in neovascular age-related macular degeneration and changes during photodynamic therapy. Documenta Ophthalmologica. 2007; 115:69–76.	50 eyes of 50 patients plus 13 control eyes	77.5 (61–92) Patient 72.8 (56–88) control	43 classic CNV AMD 7 classic with occult CNV AMD	Median 6/37.5 Patient 6/6 control	Pre-PDT Central segment amp deficit 59.7 Ring 2 amp deficit 13.6 Ring 3 amp deficit 3.2 when compared to controls no statistically significant latency deficit for any ring when compared to controls Post-PDT the deficits remain largely unchanged	During 12 months	Not given	mfERG P1 response amplitude density increases at six months and returns to baseline at 12 months
Mackay et al. Multifocal electroretinography as a predictor of maintenance of vision after photodynamic therapy for neovascular age-related macular degeneration. Documenta Ophthalmologica. 2008; 116(1):13–8.	39 eyes of 39 patients	77.1 (74.7–79.1)	34 classic CNV AMD 5 classic with occult	Median 48.0 letters logMAR	Ring 1 P1 amp 18.5 Ring 2 P1 amp 19.6 Ring 3 P1 amp 17.1 Ring 1 P1 lat 39.5 Ring 2 P1 lat 37.8 Ring 3 P1 lat 35.7	12 months (VA not mfERG)	59% lost less than 15 letters on the ETDRS chart over 12 months	Not undertaken—mfERG undertaken prior to PDT as a predictor for vision maintenance post-PDT. Large central mfERGs prior to PDT increase the probability of a response to PDT in neovascular AMD

Amp amplitude in nV/deg², Lat latency in ms

the need for objective measures of retinal integrity when monitoring the efficacy of clinical intervention.

Feigl et al. used the rod-mfERG and cone-mfERG to determine the effects of multiple PDT treatments in a case report of five eyes showing transient reduction in cone-mfERG waveforms and then recovery over time in all eyes and similar findings for rod-mfERG in four out of five eyes, possibly caused by choroidal hypoperfusion. However, baseline rod-mfERG responses were poor, very small and the test demanding for patients [74].

With the recent implementation of costly intravitreal ranibizumab treatment for AMD with CNV, greater impetus has been given to looking at ways of diagnosing, monitoring and treating AMD earlier to preserve vision. In a study of nine patients who received intravitreal bevacizumab for the treatment of exudative AMD, mfERGs were performed pre- and post-treatment [55]. A linear relationship was found between visual acuity and P1 response amplitudes, suggesting that bevacizumab improved retinal function. mfERG parafoveal retinal response density improvement 3 months post-bevacizumab has been demonstrated in research by Moschos et al. [75] when studying eighteen eyes with CNV. Correlation between mfERG retinal response density in the central fifteen degrees and retinal thickness has been demonstrated in four eyes post-bevacizumab treatment, resulting in improvement of mfERG macular function responses with reduction in retinal thickness as measured by optical coherence tomography, although in this study ISCEV mfERG guidelines were replaced with a customised experimental m-sequence technique [76]. Ranibizumab efficacy has been investigated in a small study of three eyes using mfERG with a reduction in central and peripheral amplitudes being evident after three treatments when compared to age-matched normal eyes [77]. Further studies are required in the area of anti-vascular endothelial growth factor (anti-VEGF) agents, both singularly and in combination treatments, to test the efficacy of different dosing regimes and the mfERG could have an important role for assessing retinal function within this area.

The role of nutrition in retinal health may prove to become an integral part in the management of ARM. Parisi et al. [54] looked at the influence of short-term carotenoid and antioxidant supplementation on retinal function in ARM. They demonstrated that in the central five degrees, ARM subjects treated with

nutritional supplementation showed an increase in mfERG amplitudes after 6 months when compared with controls.

Conclusion and future directions

It is important to identify individuals who are at most risk of developing the ARM, so that interventions and lifestyle modifications can be targeted appropriately. In asymptomatic eyes with normal visual acuity, sensitive but reproducible tests of macular function will become more important to detect the earliest signs of ARM. The objectivity and the topographical mapping of the mfERG allow localised retinal functional deficits in ARM can be observed over time. Evidence also suggests that mfERG can be used to monitor effectiveness of surgical and clinical intervention. Experimental mfERG techniques as discussed, have shown some interesting findings and although experimental at this stage, may provide additional information about the onset and progression of ARM with time. Complementary subjective measurement techniques such as microperimetry may document disease progression and treatment monitoring in macular function more effectively than visual acuity alone [78].

Acknowledgments The authors thank Dr Mohammad Laiquzzaman for helpful editorial comments.

Competing Interests None.

References

1. Klein R, Klein BEK, Tomany SC, Meuer SM, Huang GH (2002) Ten-year incidence and progression of age-related maculopathy. *Ophthalmology* 109:1767–1779
2. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, de Jong PTVM, Klaver CCW, Klein BEK, Klein R, Mitchell P, Sarks JP, Sarks SH, Soubrane G, Taylor HR, Vingerling JR (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. *Surv Ophthalmol* 39:367–374
3. Kaur C, Foulds WS, Ling EA (2008) Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. *Prog Retin Eye Res* 27:622–647
4. Moore DJ (1995) Age-related variation in the hydraulic conductivity of bruch's membrane. *Invest Ophthalmol Vis Sci* 36:1290–1297
5. Zarbin M (2004) Current concepts in the pathogenesis of age-related macular degeneration. *Arch Ophthalmol* 122:598–614

6. Feigl B, Lovie-Kitchin J, Brown B (2005) Objective functional assessment of age-related maculopathy: a special application for the multifocal electroretinogram. *Clin Exp Optom* 88:304–312
7. Heckenlively JR, Arden GB (2006) Principles and practical of clinical electrophysiology of vision, 2nd edn. MIT press, Cambridge, MA
8. Grunwald JE, Metelitsina TI, DuPont JC, Ying GS, Maguire MG (2005) Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. *Invest Ophthalmol Vis Sci* 46:1033–1038
9. Jackson GR, McGwin JG, Phillips JM, Klein R, Owsley C (2006) Impact of aging and age-related maculopathy on inactivation of the a-wave of the rod-mediated electroretinogram. *Vision Res* 46:1422–1431
10. Walter P, Widder RA, Luke C, Konigsfeld P, Brunner R (1999) Electrophysiological abnormalities in age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 237:962–968
11. Marcus M, Merin S, Wolf M, Feinsod M (1983) Electrophysiologic tests in assessment of senile macular degeneration. *Ann Ophthalmol* 15:235–238
12. Holopigian K, Seiple W, Greenstein V, Kim D, Carr RE (1997) Relative effects of aging and age-related macular degeneration on peripheral visual function. *Optom Vis Sci* 74:152–159
13. Birch DG, Anderson JL (1992) Standardized full-field electroretinography—normal values and their variation with age. *Arch Ophthalmol* 110:1571–1576
14. Scullica L, Falsini B (2001) Diagnosis and classification of macular degenerations: an approach based on retinal function testing. *Doc Ophthalmol* 102:237–250
15. Hogg RE, Chakravarthy U (2006) Visual function and dysfunction in early and late age-related maculopathy. *Prog Retin Eye Res* 25:249–276
16. Bach MHM (2006) The origin of the pattern electroretinogram. In: Heckenlively JR, Arden GB (eds) Principles and practical of clinical electrophysiology of vision, MIT Press, Cambridge, MA, pp 185–196
17. Holder GE (2001) Pattern electroretinography (PERG) and an integrated approach to visual pathway diagnosis. *Prog Retin Eye Res* 20:531–561
18. Trick GL (2003) Beyond visual acuity: new and complementary tests of visual function. *Neurol Clin of N Am* 21:363–386
19. Mackay AM, Brown MC, Hagan RP, Fisher AC, Grierson I, Harding SP (2007) Deficits in the electroretinogram in neovascular age-related macular degeneration and changes during photodynamic therapy. *Doc Ophthalmol* 115:69–76
20. Neveu MM, Tufail A, Dowler JG, Holder GE (2006) A comparison of pattern and multifocal electroretinography in the evaluation of age-related macular degeneration and its treatment with photodynamic therapy. *Doc Ophthalmol* 113:71–81
21. Oner A, Karakucuk S, Mirza E, Erkilic K (2005) The changes of pattern electroretinography at the early stage of photodynamic therapy. *Doc Ophthalmol* 111:107–112
22. Arden GB, Bankes JL (1966) Foveal electroretinogram as a clinical test. *Br J Ophthalmol* 50:740
23. Birch DG, Fish GE (1988) Focal cone electroretinograms—aging and macular disease. *Doc Ophthalmol* 69:211–220
24. Bankes JL (1967) The foveal electroretinogram. *Trans Ophthalmol Soc U K* 87:249–262
25. Seiple WH, Siegel IM, Carr RE, Mayron C (1986) Evaluating macular function using the focal erg. *Invest Ophthalmol Vis Sci* 27:1123–1130
26. Sandberg MA, Miller S, Gaudio AR (1993) Foveal cone ergs in fellow eyes of patients with unilateral neovascular age-related macular degeneration. *Invest Ophthalmol Vis Sci* 34:3477–3480
27. Remulla JFC, Gaudio AR, Miller S, Sandberg MA (1995) Foveal electroretinograms and choroidal perfusion characteristics in fellow eyes of patients with unilateral neovascular age-related macular degeneration. *Br J of Ophthalmol* 79:558–561
28. Falsini B, Serrao S, Fadda A, Iarossi G, Porrello G, Cocco F, Merendino E (1999) Focal electroretinograms and fundus appearance in nonexudative age-related macular degeneration—quantitative relationship between retinal morphology and function. *Graefes Arch Clin Exp Ophthalmol* 237:193–200
29. Falsini B, Piccardi M, Iarossi G, Fadda A, Merendino E, Valentini P (2003) Influence of short-term antioxidant supplementation on macular function in age-related maculopathy. A pilot study including electrophysiologic assessment. *Ophthalmology* 110:51–60
30. Binns AM, Margrain TH (2007) Evaluating retinal function in age-related maculopathy with the erg photostress test. *Invest Ophthalmol Vis Sci* 48:2806–2813
31. Sutter EE, Tran D (1992) The field topography of erg components in man. 1. The photopic luminance response. *Vision Res* 32:433–446
32. Sutter EE (1991) The fast m-transform—a fast computation of cross-correlations with binary m-sequences. *SIAM J Comput* 20:686–694
33. Palmowski AM, Sutter EE, Bearse MA, Fung W (1999) Multifocal electroretinography (mf-erg) in age-related macular degeneration. *Ophthalmology* 96:166–173
34. Lai TYY, Chan WM, Lai RYK, Ngai JWS, Li HT, Lam DSC (2007) The clinical applications of multifocal electroretinography: a systematic review. *Surv Ophthalmol* 52:61–96
35. Hood DC (2000) Assessing retinal function with the multifocal technique. *Prog Retin Eye Res* 19:607–646
36. Sutter EE (2001) Imaging visual function with the multifocal m-sequence technique. *Vision Res* 41:1241–1255
37. Sutter E (2000) The interpretation of multifocal binary kernels. *Doc Ophthalmol* 100:49–75
38. Gerth C (2009) The role of the erg in the diagnosis and treatment of age-related macular degeneration. *Doc Ophthalmol* 118:63–68
39. Parisi VM, Perillo LM, Tedeschi MM, Scassa CM, Gallinaro GB, Capaldo NB, Varano MM (2007) Macular function in eyes with early age-related macular degeneration with or without contralateral late age-related macular degeneration. *Retin* 27:879–890
40. Gerth C, Hauser D, Delahunt PB, Morse LS, Werner JS (2003) Assessment of multifocal electroretinogram abnormalities and their relation to morphologic characteristics in patients with large drusen. *Arch Ophthalmol* 121:1404–1414

41. Feigl B (2007) Age-related maculopathy in the light of ischaemia. *Clin Exp Optom* 90:263–271
42. Lai TYY, Chan W-M, Lam DSC (2004) Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. *Am J Ophthalmol* 137:826–833
43. Kretschmann U, Seeliger M, Ruether K, Usui T, Zrenner E (1998) Spatial cone activity distribution in diseases of the posterior pole determined by multifocal electroretinography. *Vision Res* 38:3817–3828
44. Huang S, Wu D, Jiang F, Ma J, Wu L, Liang J, Luo G (2000) The multifocal electroretinogram in age-related maculopathies. *Doc Ophthalmol* 101:115–124
45. Heinemann-Vernaleken B, Palmowski AM, Allgayer R, Ruprecht KW (2001) Comparison of different high resolution multifocal electroretinogram recordings in patients with age-related maculopathy. *Graefes Arch Clin Exp Ophthalmol* 239:556–561
46. Li J, Tso MOM, Lam TT (2001) Reduced amplitude and delayed latency in foveal response of multifocal electroretinogram in early age related macular degeneration. *Br J Ophthalmol* 85:287–290
47. Chen CZ, Wu LZ, Wu DZ, Huang SZ, Wen F, Luo GW, Long SX (2004) The local cone and rod system function in early age-related macular degeneration. *Doc Ophthalmol* 109:1–8
48. Feigl B, Brown B, Lovie-Kitchin J, Swann P (2006) Postreceptoral adaptation abnormalities in early age-related maculopathy. *Vis Neurosci* 23:863–870
49. Feigl B, Brown B, Lovie-Kitchin J, Swann P (2004) Cone-mediated multifocal electroretinogram in early age-related maculopathy and its relationships with subjective macular function tests. *Curr Eye Res* 29:327–336
50. Feigl B, Brown B, Lovie-Kitchin J, Swann P (2006) The rod-mediated multifocal electroretinogram in aging and in early age-related maculopathy. *Curr Eye Res* 31:635–644
51. Feigl B, Brown B, Lovie-Kitchin J, Swann P (2005) Adaptation responses in early age-related maculopathy. *Invest Ophthalmol Vis Sci* 46:4722–4727
52. Feigl B, Brown B, Lovie-Kitchin J, Swann P (2005) Cone- and rod-mediated multifocal electroretinogram in early age-related maculopathy. *Eye* 19:431–441
53. Feigl B, Brown B, Lovie-Kitchin J, Swann P (2005) Monitoring retinal function in early age-related maculopathy: visual performance after 1 year. *Eye* 19:1169–1177
54. Parisi V, Tedeschi M, Gallinaro G, Varano M, Saviano S, Piermarocchi S (2008) Carotenoids and antioxidants in age-related maculopathy Italian study: multifocal electroretinogram modifications after 1 year. *Ophthalmology* 115:324–333 e322
55. Karanjia R, Eng KT, Gale J, Sharma S, ten Hove MW (2008) Electrophysiological effects of intravitreal avastin (bevacizumab) in the treatment of exudative age-related macular degeneration. *Br J Ophthalmol* 92:1248–1252
56. Jiang LB, Jin CJ, Wen F, Huang SZ, Wu DZ, Wu LZ (2003) The changes of multifocal electroretinography in the early stage of photodynamic therapy for choroidal neovascularization. *Doc Ophthalmol* 107:165–170
57. Palmowski AM, Allgayer R, Heinemann-Vernaleken B, Ruprecht KW (2002) Influence of photodynamic therapy in choroidal neovascularization on focal retinal function assessed with the multifocal electroretinogram and perimetry. *Ophthalmology* 109:1788–1792
58. Mackay AM, Brown MC, Grierson I, Harding SP (2008) Multifocal electroretinography as a predictor of maintenance of vision after photodynamic therapy for neovascular age-related macular degeneration. *Doc Ophthalmol* 116:13–18
59. Feigl B (2009) Age-related maculopathy—linking aetiology and pathophysiological changes to the ischaemia hypothesis. *Prog Retin Eye Res* 28:63–86
60. Nabeshima T, Tazawa Y, Mita M, Sano M (2002) Effects of aging on the first and second-order kernels of multifocal electroretinogram. *Jpn J Ophthalmol* 46:261–269
61. Mohidin N, Yap MKH, Jacobs RJ (1999) Influence of age on the multifocal electroretinography. *Ophthalmic Physiol Optics* 19:481–488
62. Seiple W, Vajaranant TS, Szlyk JP, Clemens C, Holopigian K, Paliga J, Badawi D, Carr RE (2003) Multifocal electroretinography as a function of age: the importance of normative values for older adults. *Invest Ophthalmol Vis Sci* 44:1783–1792
63. Hood DC, Bach M, Brigell M, Keating D, Kondo M, Lyons JS, Palmowski-Wolfe AM (2008) ISCEV guidelines for clinical multifocal electroretinography (2007 edition). *Doc Ophthalmol* 116:1–11
64. Hood DC, Wladis EJ, Shady S, Holopigian K, Li J, Seiple W (1998) Multifocal rod electroretinograms. *Invest Ophthalmol Vis Sci* 39:1152–1162
65. Feigl B, Stewart IB, Brown B, Zele AJ (2008) Local neuroretinal function during acute hypoxia in healthy older people. *Invest Ophthalmol Vis Sci* 49:807–813
66. Feigl B, Stewart I, Brown B (2007) Experimental hypoxia in human eyes: implications for ischaemic disease. *Clin Neurophysiol* 118:887–895
67. Feigl B, Brown B, Lovie-Kitchin J, Swann P (2007) Functional loss in early age-related maculopathy: the ischaemia postreceptoral hypothesis. *Eye* 21:689–696
68. Gerth C, Delahunt PB, Alam S, Morse LS, Werner JS (2006) Cone-mediated multifocal electroretinogram in age-related macular degeneration—progression over a long-term follow-up. *Arch Ophthalmol* 124:345–352
69. Parisi V, Perillo L, Tedeschi M, Scassa C, Gallinaro G, Capaldo N, Varano M (2007) Macular function in eyes with early age-related macular degeneration with or without contralateral late age-related macular degeneration. *Retin-J Retin Vitreous Dis* 27:879–890
70. Husain D, Kramer M, Kenny AG, Michaud N, Flotte TJ, Gragoudas ES, Miller JW (1999) Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. *Invest Ophthalmol Vis Sci* 40:2322–2331
71. Rütger KB K, Schwartz R, Hassenstein A, Richard G (2003) Testing central retinal function with multifocal electroretinography before and after photodynamic therapy. *Ophthalmology* 100:459–464
72. Catala-Mora J, Castany-Aregall M, Berniell-Trota JA, Arias-Barquet L, Roca-Linares G, Jurgens-Mestre I (2005) Multifocal electroretinogram and age-related macular degeneration. *Arch Soc Esp Oftalmol* 80:395–404

-
73. Moschos MM, Panayotidis D, Theodosiadis G, Moschos M (2004) Assessment of macular function by multifocal electroretinogram in age-related macular degeneration before and after photodynamic therapy. *J Fr Ophthalmol* 27:1001–1006
 74. Feigl B, Brown B, Lovie-Kitchin J, Lee L (2005) Dynamics of retinal function after multiple photodynamic therapies in age-related macular degeneration: a report of cases. *Doc Ophthalmol* 111:135–148
 75. Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea C, Loukianou E, Moschos M (2007) Intravitreal use of bevacizumab (avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. *Doc Ophthalmol* 114:37–44
 76. Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiologic findings after intravitreal bevacizumab (avastin) treatment. *Retin-J Retin Vitreous Dis* 26:270–274
 77. Feigl B, Greaves A, Brown B (2007) Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity. *Clin Ophthalmol* 1:167–175
 78. Parravano M, Oddone F, Tedeschi M, Lomoriello DS, Chiaravalloti A, Ripandelli G, Varano M (2009) Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab. *Retin-J Retin Vitreous Dis* 29:329–334